Biopharma
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi
Iovance Biotherapeutics’ stock $IOVA dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales predictions and reported lower-than-expected sales for its new cell therapy
May 11, 2025
No Comments
